NASDAQ OMX

Deflamo AB: Nyhetsuppdatering kundläge maj 2017

31.5.2017 16:21 | NASDAQ OMX

Dela

Pressmeddelande Deflamo AB

Informationsmemorandum för den pågående företrädesemissionen i Deflamo AB, med teckningstid 26 maj - 9 juni 2017, finns på bolagets hemsida www.deflamo.com Erbjudandet avser teckning av nyemitterade aktier av serie B, till en kurs om 0,80 kr per styck. Intervju med VD, Johnny Bodin, kan läsas på www.investerarbrevet.se och www.feminvest.nu

 

Nyhetsuppdatering kundläge - Deflamo

Malmö den 31 maj 2017

Under maj månad har slutliga produktionstester genomförts hos två större internationella industrikoncerner inom PVC-området. Båda med bra resultat. Under andra halvan av juni inväntas kundernas utvärderingar av dessa och därefter eventuella certifieringar av deras nya produkter. Vid positiva besked ser vi fram emot order under kvartal tre och/eller fyra.  

"Vi har arbetat med de här två projekten under ca två års tid" säger Dennis Skog, säljansvarig på Deflamo.  "Utvecklingsarbete, labbtester och mindre pilottester tar den tiden i de branscher där våra kunder verkar. Nu närmar vi oss dock slutfasen och det är med stor spänning vi ser fram emot resultaten av de slutliga utvärderingarna och de möjliga certifieringarna", fortsätter han. "Jag följer spänt det som händer hos både de här två projekten, men också ett antal andra som också närmar sig samma läge. Att arbeta långsiktigt, målmedvetet och med kundfokus är en viktig strategi för oss."

Johnny Bodin, VD på Deflamo, kommenterar; "Visst kan det kännas frustrerande när kunderna skjuter fram sina produktionstester, men det känns desto bättre när de väl genomförs och, som i dessa fall, med lyckade resultat. Det blir samtidigt ett kvitto på att vår affärsmodell med ett djupare tekniskt samarbete med kunden fungerar. Det ger både oss och kunden möjligheter att utvecklas.

På grund av sekretessavtal med kundföretagen kan Deflamo inte delge vilka bolag det rör sig om.

Läs mer om Deflamo AB på www.deflamo.com

För ytterligare information, vänligen kontakta:

Johnny Bodin, VD                                                           Dennis Skog, Sales manager
Tel: +46 (0)700 92 07 39                                                  Tel: +46 (0)72 858 21 20
E-mail: johnny.bodin@deflamo.com                                  E-mail: dennis.skog@deflamo.com

Om Deflamo
Deflamo är ett specialkemiföretag som utvecklar, producerar och marknadsför miljömässigt överlägsna flamskyddsmedel under produktnamnet Apyrum. Apyrum är ett patenterat, miljöanpassat och biologiskt
nedbrytbart alternativ till farliga flamskyddsmedel som är skadliga för miljö och hälsa. Deflamo AB är listat på Nasdaq First North och Avanza är bolagets Certified Advisor.
Bolaget har anlitat Eminova Fondkommission AB som finansiell rådgivare och emissionsinstitut för den kommande företrädesemissionen.




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Deflamo AB via Globenewswire

Om

NASDAQ OMX
NASDAQ OMX



Följ NASDAQ OMX

Skriv in din e-postadress så får du ett mejl när vi har något nytt att berätta.

Senaste nyheterna från NASDAQ OMX

Forterra Announces Definitive Agreement with Thompson Pipe Group26.6.2017 14:00Pressmeddelande

Thompson Pipe Group to Acquire Forterra's U.S. Concrete and Steel Pressure Pipe Assets Forterra to Acquire Thompson Pipe's Drainage Pipe & Products Manufacturing Facility with a Strategic Position in Houston Market IRVING, Texas, June 26, 2017 (GLOBE NEWSWIRE) -- Forterra, Inc. ("Forterra" or the "Company") (Nasdaq:FRTA), a leading manufacturer of water infrastructure pipe and products in the United States and Eastern Canada, today announced it has entered into a definitive agreement to sell the U.S. concrete and steel pressure pipe assets of its Water Pipe and Products business segment to Thompson Pipe Group. The transaction is subject to customary closing conditions and is expected to close in the third quarter of 2017.  Under the terms of the agreement, an affiliate of Thompson Pipe Group will acquire assets related to five Forterra manufacturing facilities and a fittings facility. Forterra will receive approximate

Nasdaq Closing Cross Calculates Russell US Indexes Reconstitution for the 14th Consecutive Year24.6.2017 01:52Pressmeddelande

A new record $28.9 billion traded at the closing cross in a Russell reconstitution NEW YORK, June 23, 2017 (GLOBE NEWSWIRE) -- Nasdaq (Symbol: NDAQ) today announced the Nasdaq Closing Cross was used for the 14th consecutive year to rebalance Nasdaq-listed securities in the entire family of  Russell US Indexes, part of leading global index provider FTSE Russell, during its annual reconstitution. More than 972 million shares representing a record $28.9 billion were executed in the Nasdaq Closing Cross in 0.861 seconds across some 2,499 Nasdaq-listed stocks. The previous record for dollars traded at the closing cross in a Russell reconstitution was $21.1 billion in 2015. "For the 14th consecutive year of partnering with FTSE Russell on the rebalance, we witnessed the advanced capabilities and market integrity of Nasdaq's INET technology platform resulting in transparent and efficient price discovery which benefits issuers and investors alike,&quot

LifeSci Advisors' Board Placement Initiative Announces Ninth Board Placement23.6.2017 17:52Pressmeddelande

NEW YORK, June 23, 2017 (GLOBE NEWSWIRE) -- LifeSci Advisors, a leading life sciences-focused investor relations consultancy, announced today the ninth placement of a female executive to a life sciences company board as part of their Board Placement Initiative (BPI), a program launched a year ago with the goal to connect female executives in the life sciences industry with companies looking for board candidates. LifeSci is pleased to share news of the appointment of Jean M. Franchi to the Board of Directors of Biophytis, a biotech company listed on Euronext Paris (ALBPS) focused on drugs that target diseases of aging, with drug candidates in clinical development for dry AMD and Sarcopenia. "I'm honored to join the Biophytis board, and look forward to helping the company achieve a more global presence as it advances its portfolio of innovative therapies addressing unmet needs associated with aging," said Ms. Franchi. "I want to extend my kind thanks to LifeSci

Fentress Architects Announces its Annual Student Global Challenge23.6.2017 09:00Pressmeddelande

6th edition invites students to re-envision the terminal building in the year 2075 Denver, Colorado, June 23, 2017 (GLOBE NEWSWIRE) -- Fentress Architects, based in Denver, Colorado, announces the 2017 Fentress Global Challenge, an international design competition for young and student architects. As in years past, the theme, consistent with the firm's expertise in airport design and aviation, is envisioning an airport of the future.  Participants are encouraged to re-envision the terminal building in the year 2075 using one of 10 existing international airports, taking into consideration local context, technological trends, and project feasibility and passenger experience. This is the sixth year that Fentress Architects has sponsored and administered the award, which brings a First Prize of $15,000 and a summer internship at Fentress' Denver office; four additional winners will receive smaller cash awards.

Oxford Immunotec Announces National Reimbursement for the T-SPOT®.TB Test in France22.6.2017 22:50Pressmeddelande

OXFORD, United Kingdom and MARLBOROUGH, Mass., June 22, 2017 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company focused on developing and commercializing proprietary tests for the management of underserved immune-regulated conditions, today announced a decision from the French Ministry of Health and Social Affairs to reimburse interferon gamma release assays, or IGRAs, for latent TB screening in at risk patient populations. Upon implementation of the new reimbursement codes, which is expected in the next 21 days, the French Ministry of Health and Social Affairs will provide reimbursement for the T-SPOT. TB  test at a rate of approximately 60 Euros per test. About Oxford Immunotec Oxford Immunotec Global PLC is a global, high-growth diagnostics company focused on developing and commercializing proprietary tests for the management of underserved immune-r

Standard Lithium Raises $7.4 Million in Oversubscribed Financing22.6.2017 21:49Pressmeddelande

NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia, June 22, 2017 (GLOBE NEWSWIRE) -- Standard Lithium Ltd. ("Standard Lithium" or the "Company") (TSXV:SLL) (FRA:S5L) is pleased to announce that it has completed the private placement of 9,894,785 common shares at a price of $0.75 per share for gross proceeds of $7,421,089.  Interest in the placement far exceeded the expectations of the Company, and the additional amount raised provides the Company with the capital needed to advance its current projects and pursue strategic acquisitions in the lithium sector. "We are extremely pleased with the interest received in this placement, and completion represents a significant milestone for the Company," commented Anthony Alvaro, a director of the Company.  "The strong demand speaks to the growing confidence in our team, projects and futur

I vårt nyhetsrum kan du läsa de senaste nyheterna, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt nyhetsrum